CA3162689A1 — Combinations of tie-2 activators and prostaglandins and uses thereof
Assigned to Eyepoint Pharmaceuticals Inc · Expires 2021-07-15 · 5y expired
What this patent protects
Described herein are combinations of compounds effective for activation of Tie-2 and inhibition of ????? with a compound that causes agonism of a prostaglandin receptor. The methods and compositions of the invention can be used for the treatment of glaucoma, elevated intraocular …
USPTO Abstract
Described herein are combinations of compounds effective for activation of Tie-2 and inhibition of ????? with a compound that causes agonism of a prostaglandin receptor. The methods and compositions of the invention can be used for the treatment of glaucoma, elevated intraocular pressure, ocular hypertension, and associated conditions by, for example, reduction of intraocular pressure in the eye.
Drugs covered by this patent
- Xalatan (LATANOPROST) · Thea Pharma
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.